Correction: PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients

By sjmartinez • November 25, 2022

Giardiello D, Hooning MJ, Hauptmann M, Keeman R, Heemskerk-Gerritsen BAM, Becher H, Blomqvist C, Bojesen SE, Bolla MK, Camp NJ, Czene K, Devilee P, Eccles DM, Fasching PA, Figueroa JD, Flyger H, García-Closas M, Haiman CA, Hamann U, Hopper JL, Jakubowska A, Leeuwen FE, Lindblom A, Lubiński J, Margolin S, Martinez ME, Nevanlinna H, Nevelsteen I, Pelders S, Pharoah PDP, Siesling S, Southey MC, van der Hout AH, van Hest LP, Chang-Claude J, Hall P, Easton DF, Steyerberg EW, Schmidt MK. Correction: PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients. Breast Cancer Res. 2022 Nov 22;24(1):82. doi: 10.1186/s13058-022-01579-z. Erratum for: Breast Cancer Res. 2022 Oct 21;24(1):69. PMID: 36419099.

Tags: Hematology/Oncology, Publications

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

Borghaei H, Ciuleanu TE, Lee JS, Pluzanski A, Caro RB, Gutierrez M, Ohe Y, Nishio M, Goldman J, Ready N, Spigel DR, Ramalingam SS, Paz-Ares ...

Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review

Dayyani F, Macarulla T, Johnson A, Wainberg ZA. Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review. Cancer Treat Rev. ...

Mitophagy is a novel protective mechanism for drug-tolerant persister (DTP) cancer cells

Li Y, Chen H, Lu D, Koeffler HP, Zhang Y, Yin D. Mitophagy is a novel protective mechanism for drug-tolerant persister (DTP) cancer cells. Autophagy. ...